Valuation : StemRIM

Market Cap 1.87TCr 12Cr 10Cr 9.92Cr 8.99Cr 17Cr 1.16TCr 17Cr 117.84Cr 45Cr 591.13Cr 46Cr 45Cr P/E 2024
-13.6x
P/E 2025 -10.2x
Enterprise Value 1.17TCr 7.61Cr 6.56Cr 6.21Cr 5.63Cr 11Cr 726.85Cr 11Cr 74Cr 28Cr 369.79Cr 29Cr 28Cr EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
52.06%
Yield 2024 *
-
Yield 2025 -
1 day-24.69%
1 week-42.31%
Current month-45.78%
1 month-47.52%
3 months-37.06%
6 months-39.80%
Current year-31.56%
1 week 177
Extreme 177
337
1 month 177
Extreme 177
368
Current year 177
Extreme 177
368
1 year 177
Extreme 177
368
3 years 177
Extreme 177
806
5 years 177
Extreme 177
1,518
10 years 177
Extreme 177
1,518
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 66 01/10/2022
Chief Executive Officer 58 25/10/2023
Chief Administrative Officer - -
Director TitleAgeSince
Director/Board Member 66 01/02/2007
Director/Board Member 58 01/03/2019
Director/Board Member 54 01/10/2019
Change 5-day change 1-year change 3-year change Capi.($)
-24.69%-42.31%-40.98%-78.02% 7.35Cr
-1.48%-5.59%+39.55%-6.16% 7.8TCr
-1.42%-4.24%-19.59%-38.20% 5.74TCr
+5.38%-1.09%+512.38%+36.80% 5.75TCr
-0.56%-2.21%-11.34%+27.29% 4.88TCr
+1.93%-2.37%-0.87%+149.45% 4.55TCr
+0.80%-1.67%+49.90%-15.98% 3.21TCr
-1.47%-4.17%+46.17%+89.12% 2.46TCr
-0.85%-8.64%-4.39%+161.31% 2.08TCr
-0.09%-3.61%+62.49%+98.37% 1.57TCr
Average -2.24%-7.72%+63.33%+42.40% 3.8TCr
Weighted average by Cap. +0.37%-3.72%+90.53%+37.19%

Financials

2024 2025
Net sales - -
Net income -202.2Cr -1.32Cr -1.13Cr -1.07Cr -97.35L -1.83Cr -125.78Cr -1.84Cr -13Cr -4.91Cr -64Cr -4.94Cr -4.84Cr -192.9Cr -1.26Cr -1.08Cr -1.02Cr -92.88L -1.74Cr -119.99Cr -1.75Cr -12Cr -4.68Cr -61Cr -4.72Cr -4.61Cr
Net Debt -841Cr -5.48Cr -4.72Cr -4.47Cr -4.05Cr -7.6Cr -523.14Cr -7.63Cr -53Cr -20Cr -266.15Cr -21Cr -20Cr -699.4Cr -4.55Cr -3.92Cr -3.72Cr -3.37Cr -6.32Cr -435.05Cr -6.35Cr -44Cr -17Cr -221.34Cr -17Cr -17Cr
Logo StemRIM
StemRIM Inc. is a Japan-based company mainly engaged in the regenerative medicine business. The Company is engaged in the development and research of medicines based on new action mechanism to promote functional regeneration and healing of biological tissue damaged and lost function due to injury or illness. The Company’s main product is stem cell regeneration-inducing medicine. The stem cell regeneration-inducing medicine is a medicine which can obtain the same therapeutic effect as regenerative medicine only by administering the medicine without using living cells and tissues.
Employees
-
Date Price Change Volume
11/26/11 JP¥180.00 -24.69% 53,03,600
10/26/10 JP¥239.00 -25.08% 1,36,500
09/26/09 JP¥319.00 -3.33% 2,65,300
08/26/08 JP¥330.00 -0.30% 3,25,000
07/26/07 JP¥331.00 +6.09% 2,83,300
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4599 Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!